Over the past two decades, cancer research has undergone a remarkable transformation. Advances in imaging and targeted therapies have shifted the focus from broad, generalized treatments to precision-driven approaches that adapt to each tumor’s molecular identity. Among the tools that have propelled this change are radiopharmaceuticals, compounds that unite radioactive isotopes with molecules designed to target cancer cells with extraordinary accuracy. These agents not only allow physicians to visualize disease progression but also to deliver therapy directly to malignant tissue. This dual role of radiopharmaceuticals, diagnostic and therapeutic, has become one of the most promising frontiers in oncology, with ongoing studies suggesting that global investment in the field could exceed 25 billion USD by 2032.
Central to these advances has been the contribution of Jason S. Lewis, whose research has helped define the design of radiopharmaceuticals, their testing, and their application for patient treatment. Lewis’s research spans medicine and chemistry by integrating principles of molecular design, biological targeting, and radiometal coordination. His research has strengthened the science behind positron emission tomography (PET) imaging and established new paths for theranostic construction. This term refers to radiopharmaceuticals that diagnose and treat cancer.
The early work of Lewis in the 1990s involved the coordination chemistry of radiometals such as copper, gallium, and zirconium. He investigated the stability of these isotopes’ attachment to biological molecules to ensure they would not lose their ability to bind to cancer targets. His initial work in chelation chemistry provided the impetus for his subsequent advances, and he joined the faculty at Memorial Sloan Kettering Cancer Center (MSK) in 2008. By designing ligands that safely encapsulate radioactive metals while retaining biological activity, Lewis resolved one of the major issues facing radiopharmaceutical science: ensuring molecular stability in the human body.
As advances in molecular imaging technologies progressed, Lewis’s work shifted towards combining chemistry and immunology. His research group was among the first to demonstrate the feasibility of immunoPET. This technology combines antibodies and PET imaging to see specific cancer biomarkers. Using zirconium-89-labeled antibodies, his team developed imaging agents that tracked tumor antigens in real time. With these inventions, scientists were able to evaluate the tumors’ response to treatment and further refine therapeutic plans. ImmunoPET has become a prominent area of research globally, with over 100 clinical trials using zirconium-89-labeled antibodies documented since 2015.
Lewis’s laboratory work has been a major contributor to this growing area by developing new radiotracers and imaging agents for translation into clinical practice. A few of these include zirconium-89-labeled monoclonal antibodies, copper-64-labeled peptides, and gallium-68-labeled small molecules, several of which have gone from preclinical proof of principle to first-in-human studies. His group’s work developing zirconium-89-labeled trastuzumab for PET imaging of HER2-positive breast cancer was among the earliest examples of antibody-based PET imaging in the clinic.
While at MSK, Lewis has underscored the requirement to bridge the gap between discovery chemistry and clinically useful tools. This harmonizes with MSK’s mission of integrating basic science and patient care, and his work has consistently tried to bridge the gap between laboratory ingenuity and practical utility. The Radiochemistry and Molecular Imaging Probe Core, which he directed from 2008 until 2023, evolved into a flagship operation for the design and testing of new radiotracers. Under his supervision, the core produced several distinct radiopharmaceuticals for research and clinical studies. It helped in several investigator-initiated and multiinstitutional projects.
Beyond his institutional responsibilities, Lewis has contributed to the broader landscape of scientific policy and collaboration. He served as President of the Society of Radiopharmaceutical Sciences from 2022 to 2023 and of the World Molecular Imaging Society between 2014 and 2015, while also holding executive positions within the Society of Nuclear Medicine and Molecular Imaging. Through these roles, he has been involved in discussions around research funding priorities, the advancement of radiochemistry education, and the responsible application of nuclear medicine technologies.
Lewis’s work also impacts the broader scientific community. He has co-authored or published more than 350 peer-reviewed papers, and his studies have been frequently cited across radiology, chemistry, and oncology journals. His research has also been supported by sustained funding from the Department of Energy and the National Institutes of Health (NIH), as well as by private foundations with a particular interest in imaging and cancer therapeutics. Through his affiliations with the Society of Radiopharmaceutical Sciences, the World Molecular Imaging Society, and the Society of Nuclear Medicine and Molecular Imaging, Lewis has helped establish research priorities and develop collaborative research on new technologies.
The continued advances in radiopharmaceutical science demonstrate the interdisciplinary nature of medical science. Jason S. Lewis’s work shows how clinical medicine, biology, and chemistry might intersect to create technologies that will literally redefine the diagnosis and treatment of cancer. With a lifetime of steady research, he has helped develop the scientific and operational models that will underpin molecular imaging in the future. As the field shifts towards greater convergence of therapeutics and diagnostics, his work is again and again the key reference point for how precision oncology might be developed through radiochemistry-facilitated innovation.
Disclaimer: The information in this article is for informational purposes only and does not constitute medical advice. The article discusses scientific advancements in radiopharmaceuticals and precision oncology based on current research. Always consult with a healthcare professional for medical advice, diagnosis, or treatment.
